Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2025 Net Income-$10.60M-$10.60MderivedN/M vs Q4 2025 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Incomederived-$11,380,000N/M Operating Cash Flowderived-$6,228,000N/M Free Cash Flowderived-$6,247,000N/M ended Jun 30, 2026 · filed Aug 28, 2026 · 59 d after period end